Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - pravastatin sodium - tablet - 10 milligram(s) - hmg coa reductase inhibitors; pravastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - pravastatin sodium - tablet - 20 milligram(s) - hmg coa reductase inhibitors; pravastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - pravastatin sodium - tablet - 40 milligram(s) - hmg coa reductase inhibitors; pravastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

wpr healthcare limited - pravastatin sodium - tablet - 10 milligram(s) - hmg coa reductase inhibitors; pravastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

wpr healthcare limited - pravastatin sodium - tablet - 20 milligram(s) - hmg coa reductase inhibitors; pravastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

wpr healthcare limited - pravastatin sodium - tablet - 40 milligram(s) - hmg coa reductase inhibitors; pravastatin

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - tablet - 10 mg - therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. in hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: in patients with clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated total-c, ldl-c, apob, and tg levels and to increase hdl-c in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib).8 pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (fredrickson type iv). pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (fredrickson type iii)

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - tablets - pravastatin sodium 10 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute c

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 20 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets are indicated to: in patients with clinically evident chd, pravastatin sodium tablets are indicated to: pravastatin sodium tablets are indicated: pravastatin sodium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( fredrickson types i and v). hypersensitivity to any component of this medication. active liver disease or unexplained, persistent elevations of serum transaminases [see warnings and precautions (5.2)

Malta - English - Medicines Authority

accord healthcare limited - pravastatin sodium - tablet - pravastatin sodium 10 mg - lipid modifying agents